Toddlers Show Weakest Immune Defenses Against Human Metapneumovirus in Post-COVID China Survey

Human metapneumovirus, a leading cause of respiratory infections in young children, has become a growing focus of public health attention since the COVID-19 pandemic disrupted the circulation patterns of many common respiratory viruses. A new seroepidemiological study conducted in Taizhou city, in eastern China’s Zhejiang Province, now offers one of the most detailed pictures yet of how immunity to this virus is distributed across the human lifespan in the post-pandemic era. The findings, published in BMC Infectious Diseases, reveal a striking vulnerability window in toddlers and suggest that population-level immunity against the virus follows a distinctive age-related trajectory with important implications for future vaccine and prevention strategies.

The research team, led by Chang Liu and Qiang Wang of the Shanghai Institute of Infectious Disease and Biosecurity at Fudan University, together with David Hodgson of Charité Universitätsmedizin Berlin and collaborators at the Taizhou City Center for Disease Control and Prevention and the University of Hong Kong, analyzed serum samples collected between June 2 and June 30, 2024. The samples came from a community-based cross-sectional survey that used a multistage, age-stratified sampling design, with deliberate oversampling of children under five years of age to ensure that the youngest and most epidemiologically critical age groups were adequately represented. In total, 1,303 participants aged between 16 months and 93 years were included in the analysis.

Rather than simply measuring whether people had ever been exposed to the virus, the researchers focused on neutralizing antibodies, the subset of antibodies capable of directly blocking viral infection of cells. These were quantified using a fluorescence-based microneutralization assay, a laboratory technique in which serum is serially diluted and mixed with live virus before being applied to cell cultures; the presence of neutralizing activity is then detected through fluorescence-based readouts. A participant was classified as seropositive if their serum neutralized the virus at a dilution of 1:30 or greater. This approach provides a more functionally meaningful measure of protective immunity than binding-antibody tests alone, because neutralization titers correlate more closely with resistance to infection.

The central finding concerns children aged 16 to less than 36 months, who displayed the lowest antibody levels of any age group examined. Their geometric mean titer, a standard way of averaging antibody concentrations that are log-distributed across a population, stood at just 217, with a 95 percent confidence interval of 159 to 295. Only 67.8 percent of participants in this age band, 137 out of 202 children tested, were seropositive at all. In practical terms, roughly one in three toddlers in their second and third years of life lacked detectable neutralizing immunity against a virus that commonly causes bronchiolitis and pneumonia in early childhood.

The picture changes rapidly with age. Among children aged three to four years, the geometric mean titer rose to 331, and by ages five to eleven it exceeded 1,000, a level that was then maintained throughout adulthood. The oldest participants showed the strongest responses of all: adults aged 65 years and older had a geometric mean titer of 1,829, with a confidence interval of 1,620 to 2,064. From the age of six onward, seroprevalence was close to or had reached 100 percent, indicating that nearly everyone in the population had accumulated neutralizing antibodies by school age, most likely through repeated natural infections during early childhood.

Within the under-five group, the age gradient was particularly steep. The researchers calculated that for each additional year of age, neutralizing antibody titers increased by 74.7 percent, with a 95 percent confidence interval ranging from 14.4 percent to 167.0 percent. This rapid accumulation of immunity in the first years of life is consistent with the known epidemiology of human metapneumovirus, which circulates seasonally and infects a large proportion of children before their fifth birthday. The low titers observed in the 16-to-36-month window likely reflect the combination of waning maternal antibodies, limited cumulative exposure, and the immature antibody responses characteristic of early childhood.

The timing of the study adds a layer of epidemiological significance. The COVID-19 pandemic and the non-pharmaceutical interventions that accompanied it, including masking, school closures, and physical distancing, dramatically suppressed transmission of many respiratory pathogens worldwide, and human metapneumovirus was no exception. When these measures were relaxed, several respiratory viruses returned with unusual intensity and atypical seasonality, raising concerns about whether cohorts of children who grew up during the interruption had missed their usual early exposures and were now entering a period of heightened susceptibility. The Taizhou data suggest that by mid-2024, transmission had resumed sufficiently to rebuild immunity in older children, but that toddlers remained a partially unprotected reservoir of susceptibility.

One of the more intriguing aspects of the study is its exploration of the relationship between immunity to human metapneumovirus and respiratory syncytial virus, or RSV, a closely related paramyxovirus. The researchers measured IgG antibodies against the prefusion F protein of RSV, the key surface protein targeted by protective antibodies, and examined how these correlated with metapneumovirus neutralization titers. They found a statistically significant positive association: higher RSV prefusion F IgG titers were linked to higher metapneumovirus neutralizing titers, with a Spearman correlation coefficient of 0.302 and a p-value below 0.001.

The authors are careful to note that this correlation does not prove a causal mechanism. It may reflect shared epidemiological exposures, since both viruses circulate in overlapping seasonal windows and spread through similar routes, meaning that individuals with more respiratory virus exposure in general would tend to have higher titers against both. Individual differences in the vigor of immune responses could also produce the same pattern, with some people mounting stronger antibody responses to any viral challenge. A third possibility is genuine cross-reactive immunity, in which antibodies raised against one virus recognize structurally similar proteins on the other, a phenomenon documented for other paramyxoviruses. Distinguishing among these explanations will require longitudinal studies and laboratory work with cross-neutralization assays.

The practical implications of the study are considerable. No licensed vaccine or prophylactic product currently exists for human metapneumovirus, although several vaccine candidates are in development, and monoclonal antibodies and maternal immunization strategies are being explored for RSV, raising the prospect of similar approaches for its viral cousin. In the absence of immunization tools, the identification of children aged 16 to 36 months as the group with the lowest seroprevalence and weakest titers provides a clear target for surveillance and, eventually, for preventive interventions. The authors emphasize that continued monitoring of this age group is essential, both to track how post-pandemic transmission dynamics reshape the immunity landscape and to inform the design and prioritization of future vaccination programs. As the global health community absorbs the lesson that pandemic-era disruptions can leave lasting imprints on the epidemiology of common respiratory viruses, studies like this one demonstrate the value of population-based serosurveillance in pinpointing exactly where those imprints fall and who remains most at risk.

Subject of Research: Age-specific neutralizing antibody immunity against human metapneumovirus in a post-COVID-19 population in eastern China

Article Title: Age-specific neutralizing antibody levels against human metapneumovirus during the post-COVID-19 pandemic period: a cross-sectional seroepidemiological study in Taizhou city, Eastern China

Article References: Liu, C., Wang, Q., Hodgson, D., Liang, H., Zheng, B., Wu, J. T., Lin, H., & Wang, W. (2026). Age-specific neutralizing antibody levels against human metapneumovirus during the post-COVID-19 pandemic period: a cross-sectional seroepidemiological study in Taizhou city, Eastern China. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14417-w

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14417-w

Keywords: human metapneumovirus, neutralizing antibodies, seroepidemiology, cross-sectional study, post-COVID-19, respiratory syncytial virus, children, Taizhou, China, geometric mean titer, public health surveillance, paramyxovirus